Pharmacology/Pharmaceutical Industry
Cluster randomized trial: no added value of duloxetine for patients with chronic pain due to hip or knee osteoarthritis.
16 Jan, 2022 | 22:59h | UTC
Unvaccinated pregnant people are at higher risk for Covid complications and newborn deaths.
14 Jan, 2022 | 08:44h | UTCUnvaccinated pregnant people are at higher risk for Covid complications and newborn deaths – STAT
Original Study: SARS-CoV-2 infection and COVID-19 vaccination rates in pregnant women in Scotland – Nature Medicine
COVID vaccines safely protect pregnant people: the data are in.
14 Jan, 2022 | 08:43h | UTCCOVID vaccines safely protect pregnant people: the data are in – Nature
Related:
COVID-19 vaccination in pregnancy—number needed to vaccinate to avoid harm.
Editorial: Covid-19 treatments and vaccines must be evaluated in pregnancy.
AstraZeneca vaccination not linked to reduced fertility rates and adverse birth outcomes.
Study shows high effectiveness of the Pfizer mRNA COVID-19 vaccine in pregnancy.
5 Crucial Things to Know About COVID-19 Vaccines and Pregnancy.
CDC Guidance: Pregnant people should be vaccinated against COVID-19.
Cohort study: Pfizer/BioNTech COVID vaccine associated with 78% lower risk of Covid-19 in pregnancy.
Fluvoxamine for Covid-19: What Prescribers and Pharmacists Need to Know.
14 Jan, 2022 | 08:37h | UTCFluvoxamine: What Prescribers and Pharmacists Need to Know – Covid-19 Advisory for Ontario
Related:
Fluvoxamine for the early treatment of SARS-CoV-2 Infection: a review of current evidence.
Commentary on Twitter
Thinking of prescribing fluvoxamine for covid 19? Ontario has a nice infographichttps://t.co/MKT8PqlJpM
— Todd C. Lee (@DrToddLee) January 12, 2022
RCT: In patients with Parkinson disease uncontrolled with Levodopa, MAO-B inhibitors or dopamine agonists as adjuvant therapies were associated with better patient-rated quality of life compared to COMT inhibitors.
14 Jan, 2022 | 08:15h | UTC
Commentary on Twitter
In poorly controlled #ParkinsonDisease, study found adding a COMT inhibitor to existing treatment is not as good as adding a MAOB inhibitor or dopamine agonist https://t.co/0GrA2YYMbI pic.twitter.com/d4VNnom2zk
— JAMA Neurology (@JAMANeuro) December 28, 2021
Systematic Review: Ketamine for the treatment of mental health and substance use disorders.
14 Jan, 2022 | 08:08h | UTCCommentaries:
Ketamine therapy swiftly reduces depression and suicidal thoughts – University of Exeter
Ketamine May Quickly Ease Tough-to-Treat Depression – HealthDay
Phase 2 RCT: In patients with generalized pustular psoriasis, Spesolimab improved lesions at one week but was associated with infections and systemic drug reactions.
14 Jan, 2022 | 08:01h | UTCTrial of Spesolimab for Generalized Pustular Psoriasis – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Trial of Spesolimab for Generalized Pustular Psoriasis – Mount Sinai
Systematic Review: In patients with intermittent claudication, Propionyl‐L‐carnitine may improve walking distance when compared to placebo (moderate overall certainty of evidence).
14 Jan, 2022 | 08:02h | UTCPropionyl‐L‐carnitine for intermittent claudication – Cochrane Library
Summary: Propionyl-L-carnitine for intermittent claudication – Cochrane Library
RCT: In patients with immune-mediated inflammatory diseases (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, ulcerative colitis, Crohn disease, or psoriasis) treated with Infliximab, a proactive therapeutic drug monitoring protocol was more likely to lead to sustained disease control.
14 Jan, 2022 | 07:57h | UTCEffect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial – JAMA (link to abstract – $ for full-text)
Commentary on Twitter
Study found proactive therapeutic drug monitoring (TDM) compared with treatment without TDM during maintenance infliximab therapy was more likely to lead to sustained disease control over 52 weeks for patients with immune-mediated inflammatory diseases https://t.co/yfJjyADaOT pic.twitter.com/JtOfQxFFDS
— JAMA (@JAMA_current) December 21, 2021
Observational study in adolescents showed the Pfizer-BioNTech vaccine had an overall effectiveness of 94% against hospitalization and 98% against critical Covid-19.
13 Jan, 2022 | 09:00h | UTCEditorial: Sparing of Severe Covid-19 in Vaccinated Adolescents – New England Journal of Medicine
Study shows COVID-19 vaccines offer lasting protection against hospitalization and death.
13 Jan, 2022 | 09:01h | UTCNews Release: Study shows COVID-19 vaccines offer lasting protection – University of North Carolina at Chapel Hill
An observational study in South Africa estimates the Pfizer vaccine had an effectiveness of 70% against hospitalization for Covid-19 caused by the omicron variant.
13 Jan, 2022 | 08:56h | UTCCommentary: BNT162b2 still effective, but less so, against Omicron – HealthDay
RCT: Early Remdesivir in outpatients can prevent progression to severe Covid-19.
13 Jan, 2022 | 08:54h | UTCEditorial: The Goldilocks Time for Remdesivir — Is Any Indication Just Right?
Commentary: Three days of remdesivir cuts risk for severe COVID-19 in outpatients – MedicalXpress
Commentary on Twitter
Among nonhospitalized patients with Covid-19–related symptoms, a 3-day course of remdesivir resulted in an 87% lower risk of hospitalization or death than placebo. #COVID19 #IDTwitter https://t.co/YFflw5nBxB pic.twitter.com/4NCD9AcnYH
— NEJM (@NEJM) December 22, 2021
Another study showed neutralizing monoclonal antibody therapies are not effective when given after the patient is already hospitalized.
13 Jan, 2022 | 08:48h | UTCInvited Commentary: Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19
RCT: A single dose of a novel adenovirus type 5 vectored SARS-CoV-2 vaccine was safe and had 57.5% efficacy against symptomatic Covid-19 and 91.7% efficacy against severe disease in adults.
13 Jan, 2022 | 08:44h | UTCCommentaries:
Efficacy of an adenovirus type 5 vectored SARS-CoV-2 vaccine – The Lancet
The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin.
13 Jan, 2022 | 08:17h | UTCThe Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin – Drugs
Statement on therapies for high-risk, nonhospitalized patients with mild to moderate Covid-19.
12 Jan, 2022 | 09:14h | UTCSee also: What’s New in the Guidelines – NIH COVID-19 Treatment Guidelines
Statement on potential drug-drug interactions between Ritonavir-boosted Nirmatrelvir (Paxlovid) and concomitant medications; antiarrhythmics, oral anticoagulants, immunosuppressants, anticonvulsants, antineoplastics, and neuropsychiatric drugs are among the drugs of concern.
12 Jan, 2022 | 09:09h | UTCCommentaries:
Pfizer antiviral pills may be risky with other medications – NBC News
See also: What’s New in the Guidelines – NIH COVID-19 Treatment Guidelines
RCT: High-dose weekly Semaglutide (2.4 mg) resulted in increased weight loss compared to daily Liraglutide (3.0 mg).
12 Jan, 2022 | 08:55h | UTCEffect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial – JAMA (free for a limited period)
Commentary on Twitter
In this randomized clinical trial of 338 participants, mean body weight change from baseline to 68 weeks was –15.8% with semaglutide vs –6.4% with liraglutide, a statistically significant difference. https://t.co/8tktjqw4mE pic.twitter.com/BxrL1XPpKv
— JAMA (@JAMA_current) January 11, 2022
RCT: Eltrombopag added to immunosuppression is associated with improved hematologic response vs. immunosuppression alone in previously untreated patients with severe aplastic anemia.
12 Jan, 2022 | 08:46h | UTCEltrombopag Added to Immunosuppression in Severe Aplastic Anemia – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
A randomized trial comparing immunosuppression (horse ATG and cyclosporine) with the same therapy plus eltrombopag showed more rapid and complete responses with the addition of eltrombopag. https://t.co/nH7rkeCMAS pic.twitter.com/i8iTIq8FSG
— NEJM (@NEJM) January 5, 2022
Phase 2 RCT: Adjunctive ketamine with relapse prevention–based psychological therapy shows promise for the treatment of alcohol use disorder.
12 Jan, 2022 | 08:42h | UTCAdjunctive Ketamine With Relapse Prevention–Based Psychological Therapy in the Treatment of Alcohol Use Disorder – The American Journal of Psychiatry (link to abstract – $ for full-text)
Commentary: People With AUD May Benefit From Combination of Ketamine, Mindfulness Therapy – Psychiatric News Alert
RCT: In premenopausal women with breast cancer, gonadotropin-releasing hormone analogs may preserve ovarian function against chemotherapy-induced gonadotoxic effects.
11 Jan, 2022 | 02:26h | UTCEffects of Gonadotropin-Releasing Hormone Analogs on Ovarian Function Against Chemotherapy-Induced Gonadotoxic Effects in Premenopausal Women With Breast Cancer in China: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Randomized clinical trial finds administration of gonadotropin-releasing hormone analogs (GnRHa) with chemotherapy in premenopausal pts with #BreastCancer reduces risk of premature ovarian insufficiency (#POI) and promotes recovery of ovarian function. https://t.co/gymbKT9GWZ pic.twitter.com/OUOlIwPSsq
— JAMA Oncology (@JAMAOnc) December 30, 2021
Review | Newer generation antidepressants and withdrawal effects: reconsidering the role of antidepressants and helping patients to stop.
11 Jan, 2022 | 02:16h | UTC
Commentary from the author on Twitter (thread – click for more)
We were asked to write about balance of harms and benefits of antidepressants based on current knowledge for @DTB_BMJ, a BMJ journal that is famously independent and does not take pharma sponsorship/advertising https://t.co/QCg7Bo1F40 1/n
— Mark Horowitz @markhoro.bsky.social (@markhoro) December 21, 2021
RCT: In children with sickle cell anemia, hydroxyurea in moderate doses (20 mg/kg per day) is not better than low doses (10 mg/kg per day) for primary stroke prevention.
11 Jan, 2022 | 02:10h | UTCHydroxyurea for primary stroke prevention in children with sickle cell anaemia in Nigeria (SPRING): a double-blind, multicentre, randomised, phase 3 trial – The Lancet Haematology (link to abstract – $ for full-text)
Cohort Study: Ciprofloxacin exposure during pregnancy was not associated with miscarriage or major malformations in a nationwide study from Denmark.
11 Jan, 2022 | 02:08h | UTCCiprofloxacin exposure and adverse pregnancy outcomes: a Danish nationwide cohort study – BJOG (link to abstract – $ for full-text)